IRPs mission is to reduce wound infection with focus on developing countries and in disaster management settings worldwide, targeting: Surgical wounds | Contaminated & Traumatic Wounds | C-section incisional wounds. Effective wound irrigation is key to reducing infection. Irrisept is an innovative, simple, easy-to-use, robust, and versatile wound irrigation device. The device design and packaging is ideal for use in disasters, field hospitals, refugee relief, and other emergency and humanitarian aid situations. Irrisept is manufactured by Irrimax Corporation and is cleared as a Class II Medical Device in the US and other countries. Irrisept contains low concentration 0.05% Chlorhexidine Gluconate (CHG), a broad-spectrum antimicrobial preservative agent, shown to be effective against a broad spectrum of gram positive and negative bacteria, as well as several fungi and viruses. End users simply squeeze the bottle to generate controlled streams of pressurized solution. The mechanical action of the device effectively loosens and removes wound debris. Irrisept has demonstrated safety across multiple tissue types. 14 issued/pending patents across more than 40 countries. Packaged sterile for use in multiple environments. Additionally, IRPs advisory team has significant experience in emergency medicine, humanitarian aid, and austere medicine. www.infectionreductionpartners.com